Table 1.
Demographic and clinicopathological characteristics of the patients who experienced recurrence.
| All patients (n=260) | |
|---|---|
| Age (years), mean ± SD | 48.6 ± 9.7 |
| FIGO 2009 staging, n (%) | |
| I | 141 (54.2) |
| II | 101 (38.8) |
| III | 13 (5.0) |
| IV | 5 (1.9) |
| Staging categories, n (%) | |
| Early (FIGO stage IA1 to IB1) | 103 (39.6) |
| Locally advanced (FIGO stage IB2 to IIB) | 139 (53.5) |
| Advanced (FIGO stage III to IVB) | 18 (6.9) |
| Histological subtypes, n (%) | |
| SCC | 206 (79.2) |
| ADC | 45 (17.3) |
| Adenosquamous carcinoma | 9 (3.5) |
| Histological differentiation, n (%) | |
| Grade 1 | 19 (12.0) |
| Grade 2 | 78 (49.4) |
| Grade 3 | 61 (38.6) |
| Primary treatment regimens, n (%) | |
| Only chemotherapy | 1 (0.4) |
| Only radiotherapy or CCRT | 73 (28.1) |
| Radiotherapy or CCRT plus chemotherapy | 13 (5.0) |
| Surgery with/without adjuvant therapy | 173 (66.5) |
| Primary treatment with/without radiotherapy, n (%) | |
| With radiotherapy or CCRT | 155 (59.6) |
| Without radiotherapy or CCRT | 105 (40.4) |
| DFS after first treatment (months), median (range) | 17.0 (3.1-249.6) |
| Recurrent sites, n (%) | |
| Only within pelvic cavity | 133 (51.2) |
| Only beyond pelvic cavity | 48 (18.5) |
| Both within and beyond pelvic cavity | 79 (30.4) |
| Number of recurrent sites, n (%) | |
| Solitary | 57 (21.9) |
| Multiply | 203 (78.1) |
| Diagnostic regimens, n (%) | |
| Symptoms | 114 (43.8) |
| Physical examination | 33 (12.7) |
| Cervical cytology with/without hrHPV | 4 (1.5) |
| Serum biomarker | 34 (13.1) |
| Imaging | 75 (28.8) |
| Pathological evidences of recurrence, n (%) | |
| No | 100 (38.5) |
| Yes | 160 (61.5) |
| Treatment for recurrence, n (%) | |
| Radiotherapy or CCRT | 161 (61.9) |
| Surgery | 90 (34.6) |
| Chemotherapy | 137 (52.7) |
| Ablation therapy | 8 (3.1) |
| Combination therapy, n (%)* | |
| Yes | 109 (41.9) |
| No | 151 (58.1) |
| Surgical patterns, n (%) | |
| Resection of lesions | 48 (57.8) |
| Pelvic exenteration | 35 (42.2) |
| Lines of chemotherapy, median (range) | 1 (1-5) |
| Antiangiogenic therapy, n (%) | 27 (19.7) |
*As about half patients underwent combination therapy, the treatment modality number is not equal to patient number.
ADC, adenocarcinoma; CCRT, concurrent chemoradiotherapy; DFS, disease-free survival; FIGO, International Federation of Gynecology and Obstetrics; hrHPV, high-risk human papillomavirus; SCC, squamous cell carcinoma; SD, standard deviation.